thrombotic microangiopathy , TMA (Abkürzung)

Nasal septum perforation and renal thrombotic microangiopathy have been reported.

Article: Thrombotic microangiopathy in two tiger snake envenomations.

Thrombotic microangiopathy - very high mag.

Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation.

Dysmenorrhea Thrombotic microangiopathy (high dose)

Bacterial toxins are the primary cause of one category of thrombotic microangiopathy known as HUS or hemolytic uremic syndrome.

Thrombotic microangiopathy, abbreviated TMA, is a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury.

The syndrome exhibits thrombotic microangiopathy, multiple organ thrombosis, and in some cases tissue necrosis and is considered an extreme or catastrophic variant of the antiphospholipid syndrome.

TTP is characterized by thrombotic microangiopathy (TMA), the formation of blood clots in small blood vessels throughout the body, which can lead to microangiopathic hemolytic anemia and thrombocytopenia.

Eculizumab inhibits complement-mediated thrombotic microangiopathy (TMA) in patients with aHUS, a genetic disease in which a genetic deficiency of natural complement regulatory factors leads to chronic uncontrolled complement activation.

Bell WR, Chulay JD, J.E. F. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204).

Clinical trials in patients with aHUS demonstrated inhibition of thrombotic microangiopathy (TMA), the formation of blood clots in small blood vessels throughout the body, including normalization of platelets and lactate dehydrogenase (LDH), as well as maintenance or improvement in renal function.